Optimal Timing of Invasive Strategy in NSTEMI Patient: Immediate or Delayed?

Sang Yeub Lee MD., PhD.

Division of Cardiology, Department of Internal Medicine

Chungbuk National University, School of Medicine, Cheongju, South Korea

Early invasive approach in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) has been approved to improve outcomes [1]. The issue of optimal timing of routine invasive strategy has not been clarified due to confusing results of recently released randomized controlled trials (RCTs) that have compared early versus delayed invasive intervention. Several meta-analyses have indicated the potential of earlier intervention to reduce recurrent ischemia, while mortality and new MI rates were not different as compared to delayed invasive strategy [2].

The largest systemic review and meta-analysis of this issue announced early invasive strategy in NSTE-ACS patients seems to be associated with lower rates of recurrent ischemia, but higher levels of cardiac injury biomarkers, as compared with delayed invasive strategy. Mortality rates appear to be similar in the short- and midterm follow up (Figure 1) [3].

The aim of this lecture is to systematically summarize the RCTs on early versus delayed invasive strategy and to elucidate improvement of outcomes between two strategy.
Figure 1. Forest plots show comparisons of rate in mortality (panel A), new MI (panel B) and recurrent ischemia (panel C).

Reference

